-
1 Comment
Entera Bio Ltd is currently in a long term uptrend where the price is trading 137.2% above its 200 day moving average.
From a valuation standpoint, the stock is 86.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 176.0.
Entera Bio Ltd's total revenue rose by 116.7% to $221K since the same quarter in the previous year.
Its net income has increased by 34.6% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 57.0% to $-1M since the same quarter in the previous year.
Based on the above factors, Entera Bio Ltd gets an overall score of 5/5.
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | IL0011429839 |
| Sector | Healthcare |
| Industry | Biotechnology |
| PE Ratio | None |
|---|---|
| Target Price | 10 |
| Beta | 1.48 |
| Market Cap | 94M |
| Dividend Yield | None |
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis; and has completed Phase 1 clinical trial to treat stress fractures. In addition, the company is developing EB612, a tablet peptide replacement therapy for hypoparathyroidism. Further, it develops oral oxyntomodulin (OXM), a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic disorders; and GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is headquartered in Jerusalem, Israel.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ENTX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
